The Smith & Nephew (LSE: SN) share price jumped as much as 8% higher in early trading today after the medical technology giant issued a positive Q3 trading update. The company said that while it now expects underlying revenue growth for the full year to be in the lower half of its 2% to 3% range, it anticipates a trading profit margin above that achieved in 2017, as a result of a favourable legal settlement and improved cost control.
Ill come back shortly to why Id be happy to buy this FTSE 100stock today and hold it for the long term, but first I want to tell you about a smaller company in the healthcare sector. This firms share price is well over 50% below its high of last year but I believe it could be on the verge of a major recovery.
Vectura (LSE: VEC) is an industry-leading designer of medical devices that enhance the delivery and performance of inhaled products to help patients suffering from airways diseases. It also develops high-quality generic alternatives to branded therapies.
The company experienced a challenging 2017 and the decline in its share price saw it demoted from the mid-cap FTSE 250 index to the SmallCap index. However, having refocused its portfolio prioritisation and implemented initiatives to transform R&D productivity, the business has been regaining momentum recently.
Looking to next years earnings a consensus forecast increase of over 40% to 4.8p a share, according to Reuters I reckon theres considerable upside potential for investors today at a share price of 72p (market cap 479m). Id be happy to buy this stock for its recovery prospects.
Unlocking growth potential
Smith & Nephew, which last month was named by my colleague Kevin Godbold as his top stock to buy, is a bigger, more stable business than Vectura, with a market cap of 11.8bn at a current share price of 1,350p. For this reason, and because ageing populations and more active retirees provide long-term rising demand for many of its products, it is a stock I believe can thrive for decades to come.
Current chief executive Namal Nawana arrived in the summer with a track record of energising businesses to deliver better performance and greater value to shareholders. Hes confident he can do this at Smith & Nephew, with what he describes as the groups excellent product portfolio with numerous best-in-class medical technologies.
We should get full details of his strategic plans early next year, but todays update told us of one major change already being implemented, which is aimed at unlocking the firms growth potential. This is a new global commercial model, including a president responsible for each of the companys three specialised global marketing franchises: Orthopaedics, Sports Medicine/ENT and Wound.
Discount to peers
The current share price represents 18.5 times this years forecast earnings of $0.94 a share (72.9p at current exchange rates) and 17.4 times next years pencilled in $1.00 (77.5p). The earnings rating and a modest 2% running yield on a $0.35 (27.1p) dividend put Smith & Nephew on a premium rating versus the FTSE 100 average.
However, I see the shares as a buy because the company looks great value against its own sector peers. Indeed, in a research note this morning, analysts at Exane said the stock is trading at a 10-year high discount of 20% against US peer Stryker.
Our top analysts have highlighted five shares in the FTSE 100 in our special free report“5 Shares To Retire On”. To find out the names of the shares and the reasons behind their inclusion, simplyclick here to view it right away!